PLATELET-RICH FIBRIN IN REGENERATIVE WOUND THERAPY: PRELIMINARY OUTCOMES IN CANINE PATIENTS
(2) Animal and Veterinary Research Centre (CECAV), University of Trás-os-Montes e Alto Douro (UTAD), Quinta de Prados, 5000-801, Vila Real, Portugal
(3) Vasco da Gama Research Center - CIVG, University School Vasco da Gama, Av. José R. Sousa Fernandes, Campus Universitário – Bloco B, Lordemão 3020-210 Coimbra, Portugal
(4) Department of Veterinary Sciences, School of Agrarian and Veterinary Sciences, University of Trás-os-Montes e Alto Douro, Quinta de Prados, 5000-801 Vila Real, Portugal.
(5) 3B’s Research Group, I3Bs/ ICVS – Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, Parque de Ciência e Te
(6) Vetherapy - Research and Development in Biotechnology, Coimbra, Portugal
Luís C. Barros (1,3)
Maria Isabel Dias (4,5)
Maria Dos Anjos Pires (2,4)
Pedro P. Carvalho (3,6)
Platelet-Rich Fibrin (PRF) is the most recent platelet-based bioproduct used in medical procedures, as a regenerative medicine therapeutic strategy. PRF is defined as an autologous fibrin matrix, containing platelets and leukocytes, capable of enhancing soft tissue formation and bone healing, particularly in human oral and maxillofacial surgeries 1,2. PRF clots can release large levels of growth factors (GFs) for an extended period, up to 2 weeks, acting also as a space filler due to its scaffold-like function 3.
PRF is probably the most versatile and accessible platelet-enriched product available for veterinary regenerative treatments. It is a natural biocompatible healing material, accelerating the wound closure and soft skin healing. Additionally, this natural scaffold is easily made at the veterinary clinic, having minimal contamination risks when prepared with aseptic technique. Human PRFs have also been advocated to have bactericidal properties 4.
The rationale for the use of platelet-based therapies stems from the fact that platelets, upon activation, release substantial amounts of GFs and other bioactive molecules that modulate wound healing 5,6. In human clinical context, PRF has been widely studied, but veterinary-origin PRF application has been poorly explored 7.
The aim of this study was to investigate the therapeutic potential of PRF, as a biological autologous wound healing product in naturally occurring medium-sized, or small-sized non-healing wounds, on canine patients.
Our results demonstrate that PRF may be used as an inexpensive and easily obtained biological wound dressing, acting as a temporal releasing matrix, to promote an effective local healing process.
BIBLIOGRAFÍA
1. Toffler M, Toscano DDSN, Holtzclaw MSD, et al. Introducing Choukroun’s Platelet Rich Fibrin (PRF) to the Reconstructive Surgery Milieu. jouranl Implant Clin Dent 2009; 21–32.
2. Ghanaati S, Booms P, Orlowska A, et al. Advanced Platelet-Rich Fibrin: A New Concept for Cell-Based Tissue Engineering by Means of Inflammatory Cells. J Oral Implantol 2014; 40: 679–689.
3. Maawi S Al, Vizcaino CH, Dohle E, et al. Homogeneous Pressure Influences the Growth Factor Release Profiles in Solid Platelet ‑ rich Fibrin Matrices and Enhances Vascular Endothelial Growth Factor Release In The Solid Platelet ‑ rich Fibrin Plugs. Int J Growth Factors Stem Cells Dent 2018; 1: 8–16.
4. Mamajiwala AS, Sethi KS, Raut CP. Impact of different platelet-rich fibrin ( PRF ) procurement methods on the platelet count , antimicrobial efficacy , and fibrin network pattern in different age groups : an in vitro study. Clin Oral Investig. Epub ahead of print 2019. DOI: 10.1007/s00784-019-03022-8.
5. Nurden P, Youlouz-Marfak I, Siberchicot F, et al. Use of autologous platelet-rich clots for the prevention of local injury bleeding in patients with severe inherited mucocutaneous bleeding disorders. Haemophilia 2011; 17: 620–624.
6. Su CY, Kuo YP, Tseng YH, et al. In vitro release of growth factors from platelet-rich fibrin (PRF): a proposal to optimize the clinical applications of PRF. Oral Surgery, Oral Med Oral Pathol Oral Radiol Endodontology 2009; 108: 56–61.
7. Soares C, Barros L, Saraiva V, et al. Bioengineered surgical repair of a chronic oronasal fistula in a cat using autologous platelet-rich fibrin and bone marrow with a tailored 3D printed implant. J Feline Med Surg 2018; 1–9.
8. Dohan Ehrenfest DM, Pinto NR, Pereda A, et al. The impact of the centrifuge characteristics and centrifugation protocols on the cells, growth factors, and fibrin architecture of a leukocyte- and platelet-rich fibrin (L-PRF) clot and membrane. Platelets 2017; 00: 1–14.
9. Kobayashi E, Flückiger L, Fujioka-Kobayashi M, et al. Comparative release of growth factors from PRP, PRF, and advanced-PRF. Clin Oral Investig 2016; 20: 2353–2360.
10. Jiménez-Aristizabal RF, López C, Álvarez ME, et al. Long-term cytokine and growth factor release from equine platelet-rich fibrin clots obtained with two different centrifugation protocols. Cytokine 2017; 97: 149–155.
